Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

EarningsNeutral

AI Analysis

Summary

Intensity Therapeutics reported Q2 2026 financial results and announced the resumption of patient treatment in the INVINCIBLE-4 Phase 2 TNBC study, with plans to resume enrollment in limited U.S. sites for the INVINCIBLE-3 Phase 3 soft tissue sarcoma study by Q3 2026.

Clinical Trial Data

Phase

Phase 2/Phase 3

Importance:4/10

Sentiment:

0.00

clinical trialenrollment restartPhase 3Phase 2soft tissue sarcomatriple negative breast cancerearnings

Related Companies

$INTS

Read the original article

Published by PR Newswire Clinical Trials on August 11, 2026 11:30 AM

Read Original